S. Kilickap Et Al. , "Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events," Future Oncology , vol.19, no.29, pp.2003-2012, 2023
Kilickap, S. Et Al. 2023. Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events. Future Oncology , vol.19, no.29 , 2003-2012.
Kilickap, S., AK, S., Dursun, O. U., ŞENDUR, M. A. N., Karadurmus, N., & Demirci, U., (2023). Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events. Future Oncology , vol.19, no.29, 2003-2012.
Kilickap, Saadettin Et Al. "Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events," Future Oncology , vol.19, no.29, 2003-2012, 2023
Kilickap, Saadettin Et Al. "Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events." Future Oncology , vol.19, no.29, pp.2003-2012, 2023
Kilickap, S. Et Al. (2023) . "Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events." Future Oncology , vol.19, no.29, pp.2003-2012.
@article{article, author={Saadettin Kilickap Et Al. }, title={Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events}, journal={Future Oncology}, year=2023, pages={2003-2012} }